Trinity Capital Inc. Provides $35 Million in Growth Capital to Neuros Medical, Inc. to Scale Pain Management Therapy Adoption

Trinity Capital Inc. (Nasdaq: TRIN), a prominent alternative asset manager, has announced a significant commitment of $35 million in growth capital to Neuros Medical, Inc., a MedTech company dedicated to alleviating chronic post-amputation pain through neuromodulation technologies. This funding aims to enhance the commercialization and adoption of Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System, which tackles pain by disrupting the peripheral nerve signals responsible for phantom limb and residual limb pain. This innovative system allows patients to activate targeted therapy on-demand, providing a viable alternative to the traditionally opioid-based pain management options that often come with undesirable side effects.

Rob Lake, Senior Managing Director at Trinity Capital, emphasized the importance of this partnership, noting that it supports a pivotal time for Neuros Medical as they transition their technology into real-world applications. The investment is expected to facilitate Neuros Medical's market expansion and accessibility to this unique pain management solution, which addresses a significant need for over two million individuals in the U.S. living with limb loss.

Neuros Medical's President and CEO, David Veino, expressed appreciation for Trinity’s ongoing support, highlighting the importance of their financial backing as the company embarks on scaling operations. The Altius system is crucial in managing pain that affects up to 80% of amputees, representing a substantial unmet medical need.

Trinity Capital, with a robust history of over $5.5 billion invested across various sectors since its inception in 2008, continues to position itself as a reliable partner for growth-oriented companies, particularly in the life sciences sector. This latest investment reaffirms their commitment to supporting innovations that improve patient outcomes in healthcare.

Trinity Capital Inc. (Nasdaq: TRIN) has made a strategic move by committing $35 million to Neuros Medical, Inc., aimed at scaling the adoption of innovative pain management therapy. This investment underlines Trinity’s position as a prominent player in the alternative asset management space, particularly within the life sciences vertical.

Neuros Medical’s Altius Direct Electrical Nerve Stimulation System represents a novel solution for chronic post-amputation pain, an area significantly underserved by traditional opioid therapies. With over two million U.S. patients affected by limb loss, the demand for effective pain relief is critical. The Altius system’s potential for delivering targeted pain management without the side effects associated with drugs is likely to attract both patients and healthcare providers alike.

For investors considering Trinity Capital, this partnership signals a bullish outlook. It highlights the company’s proactive approach in funding transformative medical technologies, which not only serve an important societal need but also have the potential for substantial returns. As Neuros Medical scales its operations and reaches more patients, it could lead to increased revenues and profitability, positively impacting the financial performance of both entities.

Moreover, Trinity Capital’s diversified investment strategy across various sectors, including growth-oriented companies in the life sciences, positions it favorably to navigate market fluctuations. The ongoing evolution of the healthcare landscape, particularly the shift away from opioid reliance, opens new avenues for innovation and investment.

Looking ahead, investors should monitor the progress of Neuros Medical in expanding its market reach and adoption of the Altius system. Successful commercialization could enhance Trinity’s portfolio and provide sustained returns, making TRIN a compelling opportunity for those seeking exposure in the burgeoning healthcare market.